Business Wire

Adbry ® (tralokinumab-ldrm) Autoinjector Now Available for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD) in the U.S.

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc. announced today the availability of the Adbry ® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States. Adbry is currently ...
WebMD

Adbry for Atopic Dermatitis: What You Need to Know

If you have atopic dermatitis, a skin condition commonly known as eczema, prescription creams or other topical medicines and moisturizers are usually enough to manage it. However, if your eczema is ...
Business Wire

LEO Pharma Announces British Journal of Dermatology Publication of Adbry™ (tralokinumab-ldrm) Pooled Safety Data in Moderate-to-Severe Atopic Dermatitis

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc, a global leader in medical dermatology, today announced that the British Journal of Dermatology published detailed results from a pooled safety analysis ...
MarketWatch

LEO Pharma Presents Final Results of ECZTEND Long-Term Adbry(R) Trial (tralokinumab-ldrm) in Patients with Moderate-to-Severe Atopic Dermatitis (AD) at Fall Clinical 2024

The MarketWatch News Department was not involved in the creation of this content. LEO Pharma Presents Final Results of ECZTEND Long-Term Adbry(R) Trial (tralokinumab-ldrm) in Patients with Moderate-to ...